Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osimertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osimertinib SCHEMBL14660911 | 1.00 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29350904 | 1.00 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14661152 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29375936 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29353024 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336957 | 0.96 | EGFR (0.92) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL18870130 | 0.95 | EGFR (0.91) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336988 | 0.94 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19254678 | 0.94 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336896 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | claimed |
| WO-2025238661-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB | BDR LIFESCIENCES PRIVATE LIMITED (IN) | 2025-11-20 | — | — | WO | claimed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2023078408-A1 | PHARMACEUTICAL COMBINATION CONTAINING MET RECEPTOR TYROSINE KINASE INHIBITOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-05-11 | — | — | WO | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| CN-114712362-A | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022120197-A1 | COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS AND STEROL REGULATORY ELEMENT-BINDING PROTEIN INHIBITORS FOR USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2022-06-09 | — | — | WO | claimed |
| CN-105848647-B | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-04-26 | — | — | CN | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4698173-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH A COMBINATION OF 3-AMINO-3-(1-METHYL-1H-IMIDAZOL-5-YL)-6-OXA-2(4,6)-QUINOLINA-1,4(1,3)-DIBENZENACYCLOHEXAPHANE-22,44-DICARBONITRILE AND AN EGFR-TKI | Kura Oncology, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2026033086-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | UNIVERSITÉ DE MONTPELLIER (FR) | 2026-02-12 | — | — | WO | disclosed |
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025238661-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB | BDR LIFESCIENCES PRIVATE LIMITED (IN) | 2025-11-20 | — | — | WO | disclosed |
| WO-2022120197-A1 | COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS AND STEROL REGULATORY ELEMENT-BINDING PROTEIN INHIBITORS FOR USES IN CANCER THERAPIES | EMORY UNIVERSITY (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-105848647-B | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-105848647-B | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022046867-A1 | OSIMERTINIB AND SELPERCATINIB COMBINATIONS FOR THE TREATMENT OF EGFR- AND RET-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-110013468-B | AZD9291 deuterated derivative pharmaceutical preparation | 北京福元医药股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3946346-A1 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |